Paclitaxel and Velcade: The rationale for a combo

Cancer Biology and Therapy

Volumn 4, Issue 6, 2005, Pages 631-634

  Finnberg, Niklas ^a   El Deiry, Wafik S ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; Bim; H ras; Paclitaxel; Velcade

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; BORTEZOMIB; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PACLITAXEL; PROTEASOME INHIBITOR; PROTEIN;

APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL DEATH; CELL KILLING; CHEMOTHERAPY; DRUG POTENTIATION; DRUG SENSITIVITY; EPITHELIUM CELL; ESOPHAGUS CANCER; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MULTIPLE MYELOMA; NEUROTOXICITY; NONHUMAN; ONCOGENE H RAS; OVARY CANCER; PROTEIN DEGRADATION; REVIEW; TUMOR CELL; TUMOR DIAGNOSIS;

EID: 25144482389     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.6.1866     Document Type: Review

References (30)

1. Kerr JF. Shrinkage necrosis of adrenal cortical cells. J Pathol 1972; 107:217-9.
2. Haslett C. Resolution of acute inflammation and the role of apoptosis in the tissue fate of granulocytes. Clin Sci (Lond) 1992; 83:639-48.
3. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together. Cancer 2000; 88:2619-28.
4. Milas L, Saito Y, Hunter N, Milross CG, Mason KA. Therapeutic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma. Radiother Oncol 1996; 40:163-70.
5. Saito Y, Milross CG, Hittelman WN, Li D, Jibu T, Peters LJ, Milas L. Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction. Int J Radiat Oncol Biol Phys 1997; 38:623-31.
6. Liu QY, Stein CA. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression. Clin Cancer Res 1997; 3:2039-46.
7. Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak upregulation and the functional status of p53. Mol Pharmacol 1998; 53:819-26.
8. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS, Longo DL. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 1998; 18:3509-17.
9. Sumantran VN, Ealovega MW, Nunez G, Clarke MF, Wicha MS. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 1995; 55:2507-10.
10. Simonian PL, Grillot DA, Nunez G. Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bel-XL and Bcl-2. Oncogene 1997; 15:1871-5.
11. Strobel T, Swanson L, Korsmeyer S, Cannistra SA. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA 1996; 93:14094-9.
12. Strobel T, Kraeft SK, Chen LB, Cannistra SA. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: A novel role for BAX during chemotherapy-induced cell death. Cancer Res 1998; 58:4776-81.
13. Blagosklonny MV, Giannakakou P, el-Deiry WS, Kingston DG, Higgs PI, Neckers L, Fojo T. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death. Cancer Res 1997; 57:130-5.
14. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995; 92:4507-11.
15. Asnaghi L, Calastretti A, Bevilacqua A, D'Agnano I, Gatti G, Canti G, Delia D, Capaccioli S, Nicolin A. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene 2004; 23:5781-91.
16. Gazitt Y, Rothenberg ML, Hilsenbeck SG, Fey V, Thomas C, Montegomrey W. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol 1998; 13:839-48.
17. Liu JR, Fletcher B, Page C, Hu C, Nunez G, Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol 1998; 70:398-403.
18. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, Bhalla K. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 1997; 42:73-81.
19. O'Reilly LA, Cullen L, Visvader J, Lindeman GJ, Print C, Bath ML, Huang DC, Strasser A. The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. Am J Pathol 2000; 157:449-61.
20. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, Adams JM, Strasser A. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286:1735-8.
21. Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P, Villunger A, Adams JM, White E. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005; 7:227-38.
22. Degenhardt K, Chen G, Lindsten T, White E. BAX and BAK mediate p53-independent suppression of tumorigenesis. Cancer Cell 2002; 2:193-203.
23. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11-22.
24. Marani M, Hancock D, Lopes R, Tenev T, Downward J, Lemoine NR. Role of Bim in the survival pathway induced by Raf in epithelial cells. Oncogene 2004; 23:2431-41.
25. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003; 22:4953-63.
26. Chauhan D, Li G, Podar K, Hideshima T, Mitsiades C, Schlossman R, Munshi N, Richardson P, Cotter FE, Anderson KC. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood 2004; 104:2458-66.
27. Lund T, Stokke T, Olsen OE, Fodstad O. Garlic arrests MDA-MB-435 cancer cells in mitosis, phosphorylates the proapoptotic BH3-only protein Bim(EL) and induces apoptosis. Br J Cancer 2005; In press.
28. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 1998; 95:1369-74.
29. Nakamura K, Yamaguchi A, Namiki M, Ishihara H, Nagasu T, Kowalczyk JJ, Garcia AM, Lewis MD, Yoshimatsu K. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: Synergistic effect in combination with paclitaxel. Oncol Res 2000; 12:477-84.
30. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 2004; 10:2968-76.